Established in 2021 by CEO Jae-Hwan Nam, SML Biopharm is an innovative South Korean biotechnology company focusing on the research and development of mRNA vaccines and therapeutics. The company combines a cutting-edge mRNA platform with an advanced lipid nanoparticle (LNP) drug delivery system to develop next-generation cancer vaccines and treatments for various diseases.

mRNA Platform: SML Biopharm has developed a differentiated mRNA platform with enhanced stability and expression, surpassing existing technologies through optimized 3′ UTR and poly(A) tail. This platform is suitable for expressing antibodies and specific proteins, inducing a strong immune response, and developing prophylactic vaccines and therapeutics. ​ Lipid Nanoparticle (LNP) Drug Delivery System: The company utilizes an AI-based advanced LNP drug delivery system, essential for delivering mRNA within the body, to enhance the effectiveness of its therapeutics.

Private

Biotech